Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5626_Библиотеки_им_академика_М_И_Перельмана.pdf
20.6 Molecular Pharmacology and Toxicology of Medicinal Plants
411
receptor-expressing cells to plant extracts or individual
compounds, examining binding affinity, kinetics, and
modulation of receptors. Insights gained from these
studies elucidate how medicinal plant compounds
impact cellular signaling pathways, neurotransmission,
or other physiological processes through interactions
with specific receptors. For example, researchers conducted the study to evaluate the possible use of medicinal plants and their compounds against SARS-CoV-2.
They investigated chemicals that may inhibit viral RNA
production and replication by targeting essential proteins and enzymes. Molecular docking studies have
revealed interesting compounds for future medication
development [136]. The medicinal herbs Glycyrrhiza
glabra, Hibiscus sabdariffa, Cichorium intybus, and others were shown to be rich in chemicals with several
immune response targets. The substances were quercetin, ursolic acid, kaempferol, and luteolin.
20.6.1.4 Pharmacodynamics, Pharmacokinetics, and Clinical Trials
Pharmacodynamics explores how active components
from medicinal plants impact the body by investigating
their interactions with receptors, enzymes, or cellular
pathways, revealing mechanisms contributing to therapeutic effects. Pharmacokinetics focuses on the absorption, distribution, metabolism, and elimination (ADME)
of bioactive compounds within the body, crucial for establishing optimal dosage regimens and evaluating bioavailability in medicinal plants. Clinical trials are essential for
assessing the safety and efficacy of medicinal plants in
humans, employing a structured process to evaluate the
impact of plant-derived compounds on specific health
conditions [137, 138]. Systematic methods of clinical trials generate crucial data guiding evidence-based medicine, enhancing the understanding of the therapeutic
potential and safety profile of medicinal plants across
various medical applications.
20.6.2 Toxicology of Medicinal Plants
Toxicology of medicinal plants involves the study of potential adverse effects and toxicity associated with the consumption or use of plant-derived compounds. Various
approaches are used to evaluate the safety profile of medicinal plants, ensuring that the therapeutic advantages outweigh the possible risks. Toxicology studies on therapeutic
plants often employ the following methods:
20.6.2.1 In Vivo Toxicity Studies
Acute toxicity studies involve administering a single large
dosage of a plant extract or chemical to test organisms,
usually rats, in order to observe any immediate adverse
consequences. This approach facilitates the determination
of possible toxicity levels and provides an introduction for
further safety assessments. For example, a study evaluated
the leaf and root methanolic extracts of Tephrosia vogelii in
albino rats. No deaths occurred within the administered
doses, suggesting safety [139]. In sub-chronic and chronic
toxicity studies, the plant extracts or chemicals are administered to test individuals over an extended period of time
to determine potential cumulative or delayed adverse
effects. Provides details regarding the long-term safety profile of medicinal plants. Genotoxicity studies focus on
assessing the capability of plant-derived compounds to
induce genetic damage or mutations. These investigations,
which include assays such as the Ames test and chromosomal aberration tests, are useful in determining the genotoxic effects of medicinal herbs.
20.6.2.2 In Vitro Toxicity Assays
In the field of in vitro toxicity assays for medicinal plants,
cell viability assessments are employed to gauge the influence of plant-derived compounds on the survival and
growth of cultured cells. Widely used assays for this purpose include the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) assay and the Alamar Blue
assay [140]. Simultaneously, cellular morphology investigations look into changes in cell shape, size, and structure
related to plant extracts, with microscopic assessment
revealing changes that show possible toxicity. Apoptosis
assays are instrumental in evaluating the capability of
plant compounds to trigger programmed cell death,
employing techniques like flow cytometry or fluorescence
microscopy to detect apoptotic changes. Cell cycle analysis
investigates modifications in cell cycle phases induced by
exposure to medicinal plant extracts, commonly utilizing
flow cytometry for the analysis of changes in cell cycle distribution. Oxidative stress assays focus on appraising the
impact of plant-derived compounds on cellular oxidative
stress, measuring parameters such as reactive oxygen species (ROS) production or antioxidant enzyme activity.
Similarly, mitochondrial function assays assess the effects
of plant extracts on mitochondrial functionality, with
measurements commonly involving mitochondrial membrane potential and respiratory chain activity. Similarly,
cytokine and inflammatory marker assays investigate the
influence of medicinal plants on the release of inflammatory markers and cytokines from cultured cells, employing
techniques like enzyme-linked immunosorbent assay
(ELISA) and other immunoassays for quantification [141].
These diverse assays collectively contribute to a comprehensive evaluation of the toxicity profile of medicinal
plants at the cellular level.
412 20 Molecular Pharmacognosy
20.6.2.3 Safety Pharmacological Studies
These studies play a pivotal role in the toxicology of
medicinal plants, ensuring the safe utilization of plantderived compounds by assessing potential adverse effects.
Cardiovascular safety is a primary concern, with procedures such as electrocardiography and hemodynamic
monitoring used to examine impacts on heart rate, blood
pressure, and cardiac function. Respiratory safety studies
evaluate the influence of plant-derived compounds on
respiratory function, measuring parameters such as respiratory rate and pulmonary function. Central nervous
system (CNS) safety studies investigate effects on sedation, motor coordination, and cognitive function through
neurobehavioral assessments and neurophysiological
measurements [142]. Gastrointestinal safety studies analyze the impact on the digestive system, examining
parameters like gastric motility and secretion through
methods such as gastrointestinal endoscopy. Renal safety
studies assess the effects on kidney function, including
parameters like glomerular filtration rate and renal blood
flow [143]. Hepatic safety studies investigate impacts on
liver function using liver function tests and histopathological examination. Hematological safety studies examine effects on blood and coagulation profiles, while
immunological safety studies assess influences on the
immune system through assays measuring cytokine production and immune cell activity. Reproductive and
developmental safety studies investigate potential impacts
on reproductive organs and fetal development, employing
fertility studies and developmental toxicity assessments.
Ocular safety studies assess the effects on ocular structures and functions, incorporating examinations and
intraocular pressure measurements. These diverse safety
pharmacological studies collectively contribute to a thorough understanding of the safety profile of medicinal
plants across various physiological aspects [144].
20.6.2.4 Risk Assessment
In the field of medicinal plant toxicology, risk assessment
entails identifying potential hazards associated with plantderived compounds and evaluating the probability of
adverse effects. This process is crucial for ensuring product safety and guiding regulatory decisions. Principle elements include hazard identification, where risks like toxic
compounds are identified and characterized. Exposure
evaluation investigates the degree and duration of exposure to these chemicals, taking into consideration variables such as the dosage as well as the administration
method [145]. Hazard characterization evaluates the toxicity of identified hazards, including potency and health
effects. Risk characterization integrates hazard identification and exposure assessment to quantify overall risk and
assess the likelihood and severity of adverse effects.
Uncertainty analysis addresses assessment uncertainties,
while risk management strategies aim to mitigate risks
through measures like setting maximum toxin levels and
implementing quality control. Post-market monitoring
and surveillance systems track safety and reassess risks
with new data.
20.7 Mechanism of Action, Efficacy, and Toxicity of Plant-derived Drugs
Plant-derived drugs have long been recognized for their
therapeutic efficacy in treating various ailments. Their
efficacy stems from the complex array of bioactive compounds they contain, which interact with biological
targets in the body to produce therapeutic effects. Many
plant-derived drugs have demonstrated remarkable efficacy in clinical studies and have been incorporated into
modern medical practice. For example, the antimalarial
drug artemisinin, derived from the plant A. annua, has
shown high efficacy against the Plasmodium parasite
in treating malaria and is a cornerstone of artemisininbased combination therapies (ACTs). Molecular pharmacognostic investigations indicate the method of action of
artemisinin, which involves the generation of free radicals that damage parasite proteins and DNA, resulting in
parasite death. While artemisinin and its derivatives are
generally well-tolerated, prolonged use at high doses
may lead to neurotoxicity and hepatotoxicity [146].
Similarly, aspirin, originally derived from willow bark,
remains one of the most widely used drugs for pain
relief, fever reduction, and anti-inflammatory effects.
Additionally, drugs such as vincristine and vinblastine,
derived from the Madagascar periwinkle plant, have
demonstrated potent chemotherapeutic agents used in
the treatment of various cancers, including leukemia and
lymphoma. Its molecular pharmacognostic studies reveal
that vinblastine and vincristine bind to tubulin, inhibiting microtubule formation and disrupting mitotic spindle assembly, leading to cell cycle arrest and apoptosis in
cancer cells. These drugs can cause dose-limiting neurotoxicity, myelosuppression, and gastrointestinal toxicity.
Digitalis glycosides obtained from the digitalis species,
like digoxin, are used to improve cardiac function in
heart failure patients; their pharmacognostic studies elucidate that digoxin inhibits the sodium-potassium
ATPase pump in cardiac myocytes, leading to increased
intracellular calcium levels and enhanced cardiac contractility. It has a narrow therapeutic window and can
cause cardiac arrhythmias, particularly in cases of overdose. Curcumin obtained from Curcuma longa exhibits
References 413
potent anti-inflammatory and anticancer properties. Its
pharmacognostic research elucidates that curcumin
modulates multiple signaling pathways involved in
inflammation and cancer progression, including NF-κB,
STAT3, and PI3K/AKT. Along with its therapeutic potential, curcumin may have low bioavailability and may
cause gastrointestinal disturbances at high doses [147].
The efficacy of plant-derived drugs often arises from
their ability to interact with specific molecular targets in
the body, such as receptors, enzymes, or signaling pathways, thereby modulating biological processes and alleviating symptoms of disease. Moreover, the synergistic
effects of multiple bioactive compounds present in plant
extracts can enhance therapeutic efficacy compared to
single isolated compounds [148].
20.8 Conclusion and Future Prospects
Molecular pharmacognosy represents a fusion of traditional pharmacognosy with modern molecular biology
techniques, offering a keen understanding of medicinal
plants’ bioactive compounds at a molecular level. By leveraging methods, such as DNA extraction, PCR, sequencing,
and metabolomics, this discipline explores the intricate
biochemical pathways underlying the synthesis of secondary metabolites in medicinal plants. These compounds,
ranging from alkaloids to flavonoids, hold immense therapeutic potential and have been integral to traditional medicine practices for centuries. However, it is the application
of molecular pharmacognosy that has driven in a new era
of comprehension and innovation in harnessing the medicinal properties of plants.
One of the key areas of focus in molecular pharmacognosy is the utilization of molecular biology techniques
for the identification and authentication of medicinal
plants. DNA barcoding, in particular, has emerged as a
powerful tool for accurately identifying plant species,
even in processed or powdered forms. By comparing specific DNA regions, such as the rbcL or matK genes, scientists can distinguish between closely related species and
detect adulterants in herbal products. This not only
ensures the quality and safety of herbal remedies but also
helps combat issues such as species substitution and
contamination.
Moreover, molecular genetics and genomics play a crucial role in elucidating the genetic diversity and evolutionary history of medicinal plants. Through techniques such
as whole-genome sequencing and population genetics
analyses, researchers can decode the genetic basis of traits
relevant to medicinal properties. For example, studies have
identified genetic variations associated with the biosynthesis of bioactive compounds like artemisinin in A. annua or
Taxol in Taxus sp. [149]. Understanding the genetic underpinnings of these traits not only informs conservation
efforts but also facilitates the breeding of improved plant
varieties with enhanced medicinal properties.
In parallel, metabolomics offers insights into the metabolic processes and chemical composition of medicinal
plants. By analyzing the complete set of metabolites present in a plant, metabolomics provides a holistic view of its
biochemical profile and biosynthetic pathways. This has
significant implications for drug discovery and development, as researchers can identify novel bioactive compounds or optimize the production of known compounds
through metabolic engineering.
Furthermore, molecular pharmacology and toxicology
shed light on the mechanisms of action, efficacy, and safety
of plant-derived drugs and herbal medicines.
Lastly, molecular pharmacognosy offers a comprehensive framework for understanding and harnessing the
therapeutic potential of medicinal plants. By integrating
molecular biology techniques, genetics, metabolomics,
pharmacology, and toxicology, this discipline enables precise identification, characterization, and exploitation of
bioactive compounds at a molecular level. As we continue
to unlock the secrets of nature’s pharmacopeia, molecular
pharmacognosy will undoubtedly remain at the forefront
of drug discovery, conservation, and personalized medicine efforts.
In the future, molecular pharmacognosy aims to integrate
omics disciplines like genomics, proteomics, and metabolomics for a comprehensive understanding. Advanced imaging techniques like MS imaging will visualize the spatial
distribution of compounds for targeted drug delivery.
Collaboration with indigenous communities will aid in sustainable plant conservation and utilization. Systems pharmacology will decode compound interactions for personalized
treatments. Synthetic biology will optimize compound production. Together, these advancements will propel drug discovery and personalized medicine forward.
References
1 Pereda-Miranda, R. and de Moraes Santos, CA. (2021).
Trends in pharmacognosy: 35 years of research on
therapeutical natural resources. Revista Brasileira De
Farmacognosia 31 (5): 503–4.
2 Cahlíková, L., Šafratová, M., Hošťálková, A. et al. (2020).
Pharmacognosy and its role in the system of profile
disciplines in pharmacy. Natural Product
Communications 15 (9): 1934578X20945450.
414 20 Molecular Pharmacognosy
3 Huang, L.Q., Yuan, Y., Cui, G.H. et al. (2009). Molecular
pharmacognosy: a new borderline discipline. Natural
Product Communications 4 (11): 1611–3.
4 Prieto, J.M. and Hanafi, M.M. (2023). Advances in
molecular regulation of prostate cancer cells by top
natural products of Malaysia. Current Issues in
Molecular Biology 45 (2): 1536–67.
5 Heinrich, M. (2010). Ethnopharmacology in the 21st
century-grand challenges. Frontiers in Pharmacology
1: 2159.
6 Liang, C., Yin, G., Lin, Z. et al. (2023). How well did
the consensus methods apply in the guideline
development of traditional Chinese medicine:
a web-based survey in China. BMC Medical Research
Methodology 23 (1): 264.
7 Chan, K., Shaw, D., Simmonds, M.S.J. et al. (2012). Good
practice in reviewing and publishing studies on herbal
medicine, with special emphasis on traditional Chinese
medicine and Chinese materia medica. Journal of
Ethnopharmacology 140 (3): 469–75.
8 Fitzgerald, M., Heinrich, M. and Booker, A. (2019).
Medicinal Plant Analysis: a Historical and Regional
Discussion of Emergent Complex Techniques. Front
Pharmacology 10: 1480.
9 Sofowora, A., Ogunbodede, E. and Onayade, A. (2013).
The role and place of medicinal plants in the strategies
for disease prevention. African Journal Of Traditional,
Complementary, and Alternative Medicines: AJTCAM
10 (5): 210–29.
10 Li, J.W. and Vederas, J.C. (2009). Drug discovery and
natural products: end of an era or an endless frontier?
Science (New York, NY) 325 (5937): 161–5.
11 Krishnamurti, C. and Rao, S.C. (2016). The isolation of
morphine by Serturner. Indian Journal of Anaesthesia
60 (11): 861–2.
12 Dal Cero, M., Saller, R., Leonti, M. et al. (2022).
Trends of Medicinal plant use over the last 2 000 years
in central Europe. Plants (Basel, Switzerland)
12 (1): 135.
13 Seeman, J.I. (2023). Revolutions in chemistry:
Assessment of six 20th century candidates (The
instrumental revolution; Hückel molecular orbital
theory; Hückel’s 4n + 2 rule; the Woodward–Hoffmann
Rules; Quantum Chemistry; and Retrosynthetic
Analysis). JACS Au 3 (9): 2378–401.
14 Hissong, R., Evans, K.R. and Evans, C.R. (2023).
Compound Identification strategies in mass
Spectrometry-based metabolomics and
pharmacometabolomics. In: Metabolomics and Its
Impact on Health and Diseases, (eds. V. Ghini, K.A.
Stringer and C. Luchinat), 43–71. Cham: Springer
International Publishing; 2023.
15 Wink, M. (2003). Evolution of secondary metabolites
from an ecological and molecular phylogenetic
perspective. Phytochemistry 64 (1): 3–19.
16 Smetanska, I. (2008). Production of secondary
metabolites using plant cell cultures. Advances in
Biochemical Engineering/Biotechnology 111: 187–228.
17 Yang, M. and Lao, L. (2019). Emerging Applications of
metabolomics in traditional Chinese medicine treating
hypertension: Biomarkers, pathways and more. Front
Pharmacology 10: 158.
18 Ernst, E. (2011). Herbal medicine in the treatment
of rheumatic diseases. Rheumatic Diseases Clinics of
North America 37 (1): 95–102.
19 Kinghorn, A.D. (2001). Pharmacognosy in the 21st
century. Journal of Pharmacy and Pharmacology
53 (2): 135–48.
20 Raja, H.A., Miller, A.N., Pearce, C.J. et al. (2017). Fungal
identification using molecular tools: a primer for the
natural products research community. Journal of
Natural Products 80 (3): 756–70.
21 Dhami, N. (2013). Trends in pharmacognosy: a modern
science of natural medicines. Journal of Herbal Medicine
3 (4): 123–31.
22 Wang, S., Kang, C-Z., Guo, L-P. et al. (2019). The
mechanism of formation of daodi herbs. In: Molecular
Pharmacognosy (ed. L-q Huang), 293–303. Singapore:
Springer Singapore.
23 Newman, D.J. and Cragg, G.M. (2004). Marine natural
products and related compounds in clinical and
advanced preclinical trials. Journal of Natural Products
67 (8): 1216–38.
24 Yan, S., Bhawal, R., Yin, Z. et al. (2022). Recent advances
in proteomics and metabolomics in plants. Molecular
Horticulture 2 (1): 17.
25 Atanasov, A.G., Zotchev, S.B., Dirsch, V.M. et al. (2021).
Natural products in drug discovery: advances and
opportunities. Nature Reviews Drug Discovery
20 (3): 200–16.
26 Thomford, N.E., Senthebane, D.A., Rowe, A. et al.
(2018). Natural products for drug discovery in the
21st century: Innovations for novel drug discovery.
International Journal of Molecular Sciences
19 (6): 1578.
27 Wang, H., Chen, Y., Wang, L. et al. (2023). Advancing
herbal medicine: Enhancing product quality and safety
through robust quality control practices. Frontiers in
Pharmacology 14: 1265178.
28 Ghatak, S., Muthukumaran, R.B. and Nachimuthu,
S.K. (2013). A simple method of genomic DNA
extraction from human samples for PCR-RFLP analysis.
Journal of Biomolecular Techniques: JBT 24 (4):
224–31.
References 415
29 Gupta, N. (2019). DNA extraction and polymerase chain
reaction. Journal of Cytology 36 (2): 116–7.
30 Najmi, A., Javed, S.A., Al Bratty, M. et al. (2022).
Modern approaches in the discovery and development
of plant-based natural products and their analogues as
potential therapeutic agents. Molecules 27 (2): 349.
31 Aboul-Maaty, N.A-F. and Oraby, H.A-S. (2019).
Extraction of high-quality genomic DNA from different
plant orders applying a modified CTAB-based method.
Bulletin of the National Research Centre 43 (1): 25.
32 Garibyan, L. and Avashia, N. (2013). Polymerase chain
reaction. The Journal of Investigative Dermatology
133 (3): 1–4.
33 Yang, S. and Rothman, R.E. (2004). PCR-based
diagnostics for infectious diseases: uses, limitations, and
future applications in acute-care settings. The Lancet
Infectious Diseases 4 (6): 337–48.
34 Nebert, D.W. and Zhang, G. (2019). Pharmacogenomics
(Chapter 16). In: Emery and Rimoin’s Principles and
Practice of Medical Genetics and Genomics, 7e (eds. R.E.
Pyeritz, B.R. Korf and W.W. Grody), 445–86.
Massachusetts: Academic Press.
35 Lauschke, V.M., Milani, L. and Ingelman-Sundberg, M.
(2017). Pharmacogenomic biomarkers for improved
drug therapy: recent progress and future developments.
The AAPS Journal 20 (1): 4.
36 Rollinson, V., Turner, R. and Pirmohamed, M. (2020).
Pharmacogenomics for primary care: an overview.
Genes 11 (11): 1337.
37 Orhan, I.E. (2014). Pharmacognosy: science of natural
products in drug discovery. BioImpacts: BI 4 (3):
109–10.
38 Valones, M.A., Guimarães, R.L., Brandão, L.A. et al.
(2009). Principles and applications of polymerase chain
reaction in medical diagnostic fields: a review. Brazilian
Journal of Microbiology 40 (1): 1–11.
39 Atanasov, A.G., Waltenberger, B., Pferschy-Wenzig, E-M.
et al. (2015). Discovery and resupply of pharmacologically
active plant-derived natural products: a review.
Biotechnology Advances 33 (8): 1582–614.
40 Dzobo, K. (2022). The role of natural products as
sources of therapeutic agents for innovative drug
discovery. Comprehensive Pharmacology 2: 408–22.
41 Srivastava, S., Gupta, S., Bhargava, M. et al. (2016). DNA
Barcoding of Medicinal Plants (Chapter 4). In:
Medicinal Plants - Recent Advances in Research and
Development (eds. H.S. Tsay, L.F. Shyur, D. Agrawal,
Y.C. Wu and S.Y. Wang), 97–127. Springer, Singapore.
42 Zhu, S., Liu, Q., Qiu, S. et al. (2022). DNA barcoding: an
efficient technology to authenticate plant species of
traditional Chinese medicine and recent advances.
Chinese Medicine 17 (1): 112.
43 Bumgarner, R. (2013). Overview of DNA microarrays:
Types, applications, and their future. Current Protocols
in Molecular Biology, Chapter 22, Unit 22.1;101:
22.1.1–11.
44 Miller, M.B. and Tang, Y.W. (2009). Basic concepts of
microarrays and potential applications in clinical
microbiology. Clinical Microbiology Reviews 22 (4):
611–33.
45 Ru, J., Li, P., Wang, J. et al. (2014). TCMSP: a database of
systems pharmacology for drug discovery from herbal
medicines. Journal of Cheminformatics 6 (1): 13.
46 Ekor, M. (2014). The growing use of herbal medicines:
issues relating to adverse reactions and challenges in
monitoring safety. Front Pharmacology 4: 177.
47 Hao, D.C. and Xiao, P.G. (2015). Genomics and
evolution in traditional medicinal plants: road to a
healthier life. Evolutionary Bioinformatics 11: 197–212.
48 Hao, D. and Xiao, P. (2020). Plant pharmacophylogeny:
past, present and future. Journal of Chinese
Pharmaceutical Sciences 29 (12): 831–54.
49 Sheldon, J.W., Balick, M.J., Laird, S.A. et al. (1997).
Medicinal plants: can utilization and conservation
coexist? Advances in Economic Botany 12: 104.
50 Sanger, F., Nicklen, S. and Coulson, A.R. (1977). DNA
sequencing with chain-terminating inhibitors. Proceedings
of the National Academy of Sciences 74 (12): 5463–7.
51 Maxam, A.M. and Gilbert, W. (1977). A new method for
sequencing DNA. Proceedings of the National Academy
of Sciences 74 (2): 560–4.
52 Chen, F., Mackey, A.J., Vermunt, J.K. et al. (2007).
Assessing performance of orthology detection strategies
applied to eukaryotic genomes. PloS One 2 (4): e383.
53 Pan, Z.X., Xu, D., Zhang, J.B. et al. (2009). Reviews in
comparative genomic research based on orthologs. Yi
Chuan 31 (5): 457–63.
54 Ohta, T. (2003). Evolution by gene duplication revisited:
differentiation of regulatory elements versus proteins.
Genetica 118: 209–16.
55 Li, X., Yang, S., Peng, L. et al. (2004). Origin and
evolution of new genes. Chinese Science Bulletin
49: 1681–6.
56 Edger, P.P. and Pires, J.C. (2009). Gene and genome
duplications: the impact of dosage-sensitivity on the fate
of nuclear genes. Chromosome Research 17: 699–717.
57 Zhang, J. (2008). Evolution by gene duplication: an
update. Trends in Ecology & Evolution 18 (6): 292–98.
58 Sun, H. and Ge, S. (2010). Review of the evolution of
duplicated genes. Chinese Bulletin of Botany 45 (1): 13.
59 Parchman, T.L., Geist, K.S., Grahnen, J.A. et al. (2010).
Transcriptome sequencing in an ecologically important
tree species: Assembly, annotation, and marker
discovery. BMC Genomics 11 (1): 1–16.
416 20 Molecular Pharmacognosy
60 Mutz, K-O., Heilkenbrinker, A., Lönne, M. et al. (2013).
Transcriptome analysis using next-generation sequencing.
Current Opinion in Biotechnology 24 (1): 22–30.
61 Xu, J., Chu, Y., Liao, B. et al. (2017). Panax ginseng
genome examination for ginsenoside biosynthesis.
Gigascience 6 (11): 1–15.
62 Xu, H., Song, J., Luo, H. et al. (2016). Analysis of the
genome sequence of the medicinal plant Salvia
miltiorrhiza. Molecular Plant 9 (6): 949–52.
63 Shen, Q., Zhang, L., Liao, Z. et al. (2018). The genome of
artemisia annua provides insight into the evolution of
Asteraceae family and artemisinin biosynthesis.
Molecular Plant 11 (6): 776–88.
64 Mochida, K., Sakurai, T., Seki, H. et al. (2017). Draft
genome assembly and annotation of Glycyrrhiza
uralensis, a medicinal legume. The Plant Journal
89 (2): 181–94.
65 Yan, L., Wang, X., Liu, H. et al. (2015). The genome of
dendrobium officinale illuminates the biology of the
important traditional Chinese orchid herb. Molecular
Plant 8 (6): 922–34.
66 Guo, L., Winzer, T., Yang, X. et al. (2018). The opium
poppy genome and morphinan production. Science
362 (6412): 343–7.
67 Cavalli-Sforza, L.L. and Feldman, M.W. (2003). The
application of molecular genetic approaches to the
study of human evolution. Nature Genetics 33 (Suppl 3):
266–75.
68 Claussnitzer, M., Cho, J.H., Collins, R. et al. (2020).
A brief history of human disease genetics. Nature 577
(7789): 179–89.
69 Van Esse, H.P., Reuber, T.L. and van der Does, D.
(2020). Genetic modification to improve disease
resistance in crops. New Phytologist 225 (1): 70–86.
70 Ishkanian, A.S., Malloff, C.A., Watson, S.K. et al. (2004).
A tiling resolution DNA microarray with complete
coverage of the human genome. Nature Genetics
36 (3): 299–303.
71 Davey, J.W., Hohenlohe, P.A., Etter, P.D. et al. (2011).
Genome-wide genetic marker discovery and genotyping
using next-generation sequencing. Nature Reviews
Genetics 12 (7): 499–510.
72 Liu, X., Liu, Y., Huang, P. et al. (2017). The genome of
medicinal plant Macleaya cordata provides new insights
into benzylisoquinoline alkaloids metabolism.
Molecular Plant 10 (7): 975–89.
73 Soltani Howyzeh, M., Sadat Noori, S.A., Shariati, J V.
et al. (2018). Comparative transcriptome analysis to
identify putative genes involved in thymol biosynthesis
pathway in medicinal plant trachyspermum ammi L.
Scientific Reports 8 (1): 13405.
74 Techen, N., Parveen, I., Pan, Z. et al. (2014). DNA
barcoding of medicinal plant material for identification.
Current Opinion in Biotechnology 25: 103–10.
75 Zargar, S.M., Raatz, B., Sonah, H. et al. (2015). Recent
advances in molecular marker techniques: insight into
QTL mapping, GWAS and genomic selection in plants.
Journal of Crop Science and Biotechnology 18: 293–308.
76 Edwards, D. and Batley, J. (2010). Plant genome
sequencing: applications for crop improvement. Plant
Biotechnology Journal 8 (1): 2–9.
77 Varshney, R.K., Nayak, S.N., May, G.D. et al. (2009).
Next-generation sequencing technologies and their
implications for crop genetics and breeding. Trends in
Biotechnology 27 (9): 522–30.
78 Yamazaki, M., Rai, A., Yoshimoto, N. et al. (2018).
Perspective: functional genomics towards new
biotechnology in medicinal plants. Plant Biotechnology
Reports 12: 69–75.
79 Grzegorczyk-Karolak, I., Wiktorek-Smagur, A. and
Hnatuszko-Konka, K. (2018). An untapped resource in
the spotlight of medicinal biotechnology: the genus
Scutellaria. Current Pharmaceutical Biotechnology
19 (5): 358–71.
80 Lalaleo, L., Testillano, P., Risueño, M-C. et al. (2018).
Effect of in vitro morphogenesis on the production of
podophyllotoxin derivatives in callus cultures of Linum
album. Journal of Plant Physiology 228: 47–58.
81 Kumari, A., Baskaran, P., Plačková, L. et al. (2018). Plant
growth regulator interactions in physiological processes
for controlling plant regeneration and in vitro
development of Tulbaghia simmleri. Journal of Plant
Physiology 223: 65–71.
82 Rosa, W.S., Martins, J.P.R., Rodrigues, E.S. et al.
(2018). Photosynthetic apparatus performance in
function of the cytokinins used during the in vitro
multiplication of Aechmea blanchetiana
(Bromeliaceae). Plant Cell, Tissue and Organ Culture
(PCTOC) 133: 339–50.
83 Espinosa-Leal, C.A., Puente-Garza, C.A. and García-
Lara, S. (2018). In vitro plant tissue culture: means for
production of biological active compounds. Planta
248: 1–18.
84 Matkowski, A. (2008). Plant in vitro culture for the
production of antioxidants: a review. Biotechnology
Advances 26 (6): 548–60.
85 Kumar, S.R., Shilpashree, H.B. and Nagegowda, D.A.
(2018). Terpene moiety enhancement by overexpression
of geranyl (geranyl) diphosphate synthase and geraniol
synthase elevates monomeric and dimeric monoterpene
indole alkaloids in transgenic Catharanthus roseus.
Frontiers in Plant Science 9: 942.
References 417
86 Zhou, Z., Tan, H., Li, Q. et al. (2018). CRISPR/Cas9-
mediated efficient targeted mutagenesis of RAS in
Salvia miltiorrhiza. Phytochemistry 148: 63–70.
87 Liu, Y., Sun, G., Zhong, Z. et al. (2017). Overexpression
of AtEDT1 promotes root elongation and affects
medicinal secondary metabolite biosynthesis in roots
of transgenic Salvia miltiorrhiza. Protoplasma 254:
1617–25.
88 Roychowdhury, D., Halder, M. and Jha, S. (2016).
Agrobacterium rhizogenes-mediated transformation in
medicinal plants: genetic stability in long-term culture.
In: Transgenesis and Secondary Metabolism, (ed. S. Jha),
p.323. Reference Series in Phytochemistry. Cham:
Springer.
89 Balasubramanian, M., Anbumegala, M., Surendran, R.
et al. (2018). Elite hairy roots of Raphanus sativus (L.)
as a source of antioxidants and flavonoids. 3 Biotech
8: 1–15.
90 Lan, X., Zeng, J., Liu, K. et al. (2018). Comparison of
two hyoscyamine 6β-hydroxylases in engineering
scopolamine biosynthesis in root cultures of Scopolia
lurida. Biochemical and Biophysical Research
Communications 497 (1): 25–31.
91 Jiao, J., Gai, Q-Y., Wang, W. et al. (2018). Remarkable
enhancement of flavonoid production in a co-cultivation
system of Isatis tinctoria L. Hairy root cultures and
immobilized Aspergillus niger. Industrial Crops and
Products 112: 252–61.
92 Kundu, S., Salma, U., Ali, M.N. et al. (2018).
Development of transgenic hairy roots and
augmentation of secondary metabolites by precursor
feeding in Sphagneticola calendulacea (L.) Pruski.
Industrial Crops and Products 121: 206–15.
93 Li, D-Z. and Pritchard, H.W. (2009). The science and
economics of ex situ plant conservation. Trends in Plant
Science 14 (11): 614–21.
94 Kastell, A., Schreiner, M., Knorr, D. et al. (2018).
Influence of nutrient supply and elicitors on
glucosinolate production in E. sativa hairy root cultures.
Plant Cell, Tissue and Organ Culture (PCTOC)
132: 561–72.
95 Xing, B., Yang, D., Liu, L. et al. (2018). Phenolic acid
production is more effectively enhanced than
tanshinone production by methyl jasmonate in Salvia
miltiorrhiza hairy roots. Plant Cell, Tissue and Organ
Culture (PCTOC) 134: 119–29.
96 Dehghan, E., Häkkinen, S.T., Oksman-Caldentey, K-M.
et al. (2012). Production of tropane alkaloids in diploid
and tetraploid plants and in vitro hairy root cultures of
Egyptian henbane (Hyoscyamus muticus L.). Plant Cell,
Tissue and Organ Culture (PCTOC) 110: 35–44.
97 Patra, N. and Srivastava, A.K. (2017). Mass production
of artemisinin using hairy root cultivation of Artemisia
annua in bioreactor. In: Bioprocessing of Plant In vitro
Systems, (eds. A. Pavlov and T. Bley), 1–17. New York:
Springer International
98 Ziv, M. (2005). Simple bioreactors for mass propagation of
plants. Plant Cell Tissue and Organ Culture 81 (3): 79–93.
99 Frankel, O.H. (1984). Genetic perspectives of germplasm
conservation. Genetic Manipulation: Impact on Man and
Society 161: 170.
100 Dornenburg, H. and Knorr, D. (1995). Strategies for the
improvement of secondary metabolite production in
plant cell cultures. Enzyme and Microbial Technology
17 (8): 674–684.
101 Kalloo, G. and Bergh, B.O. (2012). Genetic Improvement
of Vegetable Crops. London: Newnes.
102 Lenaerts, B., Collard, B.C.Y. and Demont, M. (2019).
Improving global food security through accelerated
plant breeding. Plant Science 287: 110207.
103 Lamichhane, S. and Thapa, S. (2022). Advances from
conventional to modern plant breeding methodologies.
Plant Breeding and Biotechnology 10 (1): 1–14.
104 Jones, C.M., Parrish, S. and Nielsen, D.R. (2021).
Exploiting polyploidy for markerless and plasmid-free
genome engineering in cyanobacteria. ACS Synthetic
Biology 10 (9): 2371–82.
105 Doyle, J.J. and Coate, J.E. (2019). Polyploidy, the
nucleotype, and novelty: the impact of genome doubling
on the biology of the cell. International Journal of Plant
Sciences 180 (1): 1–52.
106 Tugizimana, F., Mhlongo, M.I., Piater, L.A. et al. (2018).
Metabolomics in plant priming research: the way
forward? International Journal of Molecular Sciences
19 (6): 1759.
107 Okada, T., Afendi, F.M., Altaf-Ul-Amin, M. et al. (2010).
Metabolomics of medicinal plants: the importance of
multivariate analysis of analytical chemistry data.
Current Computer-Aided Drug Design 6 (3): 179–96.
108 Waris, M., Koçak, E., Gonulalan, E.M. et al. (2022).
Metabolomics analysis insight into medicinal plant
science. Trends in Analytical Chemistry 157: 116795.
109 Salem, M.A., Perez de Souza, L., Serag, A. et al. (2020).
Metabolomics in the context of plant natural products
research: from sample preparation to metabolite
analysis. Metabolites 10 (1): 37.
110 Surendran, K., Ranjisha, K.R., Aswati Nair, R. et al.
(2022). Genomics and Metabolomics: a strategy for
elucidation of metabolic pathways in medicinal plants.
In: Phytochemical Genomics: Plant Metabolomics and
Medicinal Plant Genomics, (eds. M.K. Swamy and A.
Kumar), 343–60. Singapore: Springer Nature Singapore.
418 20 Molecular Pharmacognosy
111 Baby, J., Thomas, T. and Dennis Thomas, T. (2022).
Metabolomics of important medicinal plants. In:
Phytochemical Genomics: Plant Metabolomics and
Medicinal Plant Genomics, (eds. M.K. Swamy and A.
Kumar), 285–317. Singapore: Springer Nature Singapore.
112 Patel, M.K., Pandey, S., Kumar, M. et al. (2021). Plants
metabolome study: emerging tools and techniques.
Plants (Basel, Switzerland) 10 (11): 2409.
113 Alseekh, S., Aharoni, A., Brotman, Y. et al. (2021). Mass
spectrometry-based metabolomics: a guide for
annotation, quantification and best reporting practices.
Nature Methods 18 (7): 747–56.
114 Courant, F., Antignac, J.P., Dervilly-Pinel, G. et al.
(2014). Basics of mass spectrometry based
metabolomics. Proteomics 14 (21–22): 2369–88.
115 Amoresano, A., and Pucci, P. (2022). Mass spectrometry in
metabolomics (Chapter 4). In: Metabolomics Perspectives,
(ed. J. Troisi), 109–47. Massachusetts: Academic Press.
116 Simpson, A.J., Simpson, M.J. and Soong, R. (2012).
Nuclear magnetic resonance spectroscopy and its key
role in environmental research. Environmental Science
& Technology 46 (21): 11488–96.
117 Emwas, A.H., Szczepski, K., Poulson, B.G. et al. (2022).
Nuclear magnetic resonance in metabolomics (Chapter
5). In: Metabolomics Perspectives, (ed. J. Troisi), 149–218.
Massachusetts: Academic Press.
118 Emwas, A.H., Roy, R., McKay, R.T. et al. (2019). NMR
spectroscopy for metabolomics research. Metabolites
9 (7): 123.
119 Moco, S. (2022). Studying metabolism by NMR-based
metabolomics. Frontiers in Molecular Biosciences
9: 882487.
120 Li, S., Siddiqa, A., Thapa, M. et al. (2023). Trackable and
scalable LC-MS metabolomics data processing using
asari. Nature Communications 14 (1): 4113.
121 Spicer, R., Salek, R.M., Moreno, P. et al. (2017).
Navigating freely available software tools for
metabolomics analysis. Metabolomics 13 (9): 106.
122 Tian, H., Li, B. and Shui, G. (2017). Untargeted LC–MS
data preprocessing in metabolomics. Journal of Analysis
and Testing 1 (3): 187–92.
123 Marco-Ramell, A., Palau-Rodriguez, M., Alay, A. et al.
(2018). Evaluation and comparison of bioinformatic
tools for the enrichment analysis of metabolomics data.
BMC Bioinformatics 19 (1): 1.
124 Myers, O.D., Sumner, S.J., Li, S., et al. (2017). Detailed
investigation and comparison of the XCMS and MZmine
2 chromatogram construction and chromatographic
peak detection methods for preprocessing mass
spectrometry metabolomics data. Analytical Chemistry
89 (17): 8689–95.
125 Fahy, E., Subramaniam, S., Brown, H.A. et al. (2005).
A comprehensive classification system for lipids.
Journal of Lipid Research 46 (5): 839–61.
126 Cruickshank-Quinn, C.I., Jacobson, S., Hughes, G. et al.
(2018). Metabolomics and transcriptomics pathway
approach reveals outcome-specific perturbations in
COPD. Scientific Reports 8 (1): 17132.
127 Kim, S.J., Kim, S.H., Kim, J.H. et al. (2016).
Understanding metabolomics in biomedical research.
Endocrinology and Metabolism (Seoul, Korea)
31 (1): 7–16.
128 Riyajan, S. (2018). Evaluation of antidiabetic activity of
the water and ethyl acetate fractions from Withania
coagulans fruits and the mechanism underlying their
hypoglycemic effects [PhD dissertation]: School of
Preclinic Institute of Science Suranaree University of
Technology.
129 Wang, Y., Chen, T., Yang, C. et al. (2022). Huangqi
Guizhi Wuwu decoction improves arthritis and
pathological damage of heart and lung in TNF-Tg mice.
Front Pharmacology 13: 871481.
130 Newman, D.J. and Cragg, G.M. (2016). Natural products
as sources of new drugs from 1981 to 2014. Journal of
Natural Products 79 (3): 629–61.
131 Ingle, K.P., Deshmukh, A.G., Padole, D.A. et al.
(2017). Phytochemicals: extraction methods,
identification and detection of bioactive compounds
from plant extracts. Journal of Pharmacognosy and
Phytochemistry 6 (1): 32–6.
132 Alamgir, A.N.M. (2018). Molecular pharmacognosy:
a new borderline discipline between molecular
biology and pharmacognosy. In: Therapeutic Use of
Medicinal Plants and their Extracts: Volume 2:
Phytochemistry and Bioactive Compounds, (ed. A.N.M.
Alamgir), 665–720. Cham: Springer International
Publishing.
133 Xiao, X., Hu, J., Xu, H. et al. (2011). Key techniques and
application progress of molecular pharmacognosy.
Chinese Herbal Medicines 106–16.
134 Yang, Z. and Yan, D. (2022). Bioassays for assessing
traditional medicines: promises and pitfalls. Frontiers
in Pharmacology 13: 839988.
135 Skripnikov, A. (2023). Bioassays for identifying and
characterizing plant regulatory peptides. Biomolecules
13 (12): 1795.
136 Shawky, E., Nada, A.A. and Ibrahim, R.S. (2020).
Potential role of medicinal plants and their constituents
in the mitigation of SARS-CoV-2: identifying related
therapeutic targets using network pharmacology and
molecular docking analyses. RSC Advances 10 (47):
27961–83.
References 419
137 Singh, D.B., Pathak, R.K. and Rai, D. (2022). From
traditional herbal medicine to rational drug discovery:
strategies, challenges, and future perspectives. Revista
Brasileira De Farmacognosia 32 (2): 147–59.
138 Kumar, R. and Sharma, M. (2018). Herbal
nanomedicine interactions to enhance
pharmacokinetics, pharmacodynamics, and therapeutic
index for better bioavailability and biocompatibility of
herbal formulations. Journal of Materials NanoScience
5 (1): 35–60.
139 Mlozi, S.H., Mmongoyo, J.A. and Chacha, M. (2020).
The in vivo toxicity evaluation of leaf and root
methanolic extracts of Tephrosia vogelii Hook. f using
animal model. Clinical Phytoscience 6 (1): 1–9.
140 Damasceno, L.M.O., Silva, A.L.N., Santos, R.F.d. et al.
(2019). Cytotoxic activity of chemical constituents and
essential oil from the leaves of Leonotis nepetifolia
(Lamiaceae). Rev Virtual Quim 11: 517–28.
141 Pferschy-Wenzig, E-M. and Bauer, R. (2015). The
relevance of pharmacognosy in pharmacological
research on herbal medicinal products. Epilepsy &
Behavior 52: 344–62.
142 Lundstrom, K., Pham, H.T. and Dinh, L.D. (2017).
Interaction of plant extracts with central nervous system
receptors. Medicines 4 (1): 12.
143 Lameire, N.H., De Vriese, A.S. and Vanholder, R.
(2003). Prevention and nondialytic treatment of
acute renal failure. Current Opinion in Critical Care
9 (6): 481–90.
144 Zhou, X., Seto, S.W., Chang, D. et al. (2016). Synergistic
effects of Chinese herbal medicine: a comprehensive
review of methodology and current research. Frontiers
in Pharmacology 7: 201.
145 Meeker, J.D. (2012). Exposure to environmental
endocrine disruptors and child development. Archives
of Pediatrics & Adolescent Medicine 166 (10): 952–8.
146 Miller, L.H. and Su, X. (2011). Artemisinin: Discovery
from the Chinese herbal garden. Cell 146 (6): 855–8.
147 Canistro, D., Chiavaroli, A., Cicia, D. et al. (2021). The
pharmacological basis of the curcumin nutraceutical
uses: an update. Pharmadvances 3 (2): 421–66.
148 Jitareanu, A., Trifan, A., Vieriu, M. et al. (2022). Current
trends in toxicity assessment of herbal medicines:
a narrative review. Processes 11 (1): 83.
149 Al-Khayri, J.M., Sudheer, W.N., Lakshmaiah, V.V. et al.
(2022). Biotechnological approaches for production of
Artemisinin, an anti-Malarial drug from Artemisia
annua L. Molecules 27 (9): 3040.
